Sab Biotherapeutics, Inc. (SABSW) — 8-K Filings

8-K Filings (20)

• SAB Biotherapeutics Files 8-K on Warrants — Dec 29, 2025 Risk: low
  On December 29, 2025, SAB Biotherapeutics, Inc. filed an 8-K report. The filing indicates that the company, formerly known as Big Cypress Acquisition Corp. unti
• SAB Biotherapeutics Files 8-K on Officer/Director Changes — Sep 30, 2025 Risk: medium
  SAB Biotherapeutics, Inc. filed an 8-K on September 30, 2025, reporting on the departure of directors or certain officers, the election of directors, the appoin
• SAB Biotherapeutics Files 8-K on Director/Officer Changes & Shareholder Votes — Sep 26, 2025 Risk: medium
  On September 26, 2025, SAB Biotherapeutics, Inc. filed an 8-K report detailing several key events. The filing includes information regarding the departure and e
• SAB Biotherapeutics Files 8-K: Agreements, Equity Sales, Bylaw Changes — Jul 21, 2025 Risk: medium
  On July 21, 2025, SAB Biotherapeutics, Inc. filed an 8-K report detailing several events. These include entering into a material definitive agreement, unregiste
• SAB Biotherapeutics Files 8-K on Shareholder Vote Matters — Jul 17, 2025 Risk: low
  On July 17, 2025, SAB Biotherapeutics, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The company, formerly known as
• SAB Biotherapeutics Files 8-K on Definitive Agreement & Asset Deal — Feb 5, 2025 Risk: medium
  SAB Biotherapeutics, Inc. (formerly Big Cypress Acquisition Corp.) filed an 8-K on February 5, 2025, reporting on events as of January 30, 2025. The filing indi
• SAB Biotherapeutics Files 8-K with Warrant Details — Jan 28, 2025 Risk: medium
  SAB Biotherapeutics, Inc. filed an 8-K on January 28, 2025, reporting on other events and financial statements. The company, formerly known as Big Cypress Acqui
• SAB Biotherapeutics Files 8-K with Financials and Warrant Details — Sep 9, 2024 Risk: medium
  SAB Biotherapeutics, Inc. filed an 8-K on September 9, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The company was formerl
• SAB Biotherapeutics Files 8-K on Officer/Director Changes — Jul 31, 2024 Risk: medium
  SAB Biotherapeutics, Inc. filed an 8-K on July 31, 2024, reporting on the departure of directors or certain officers, election of directors, appointment of cert
• SAB Biotherapeutics Files 8-K on Security Holder Vote Matters — Jun 27, 2024 Risk: medium
  SAB Biotherapeutics, Inc. filed an 8-K on June 27, 2024, to report on the submission of matters to a vote of security holders. The company, formerly known as Bi
• SAB Biotherapeutics: Director Departs, New Director Elected — May 31, 2024 Risk: low
  SAB Biotherapeutics, Inc. announced on May 26, 2024, the departure of Director Dr. Steven M. Deitcher and the election of Dr. David L. R. Gray as a new director
• SAB Biotherapeutics Files 8-K — May 21, 2024 Risk: low
  SAB Biotherapeutics, Inc. filed an 8-K on May 21, 2024, reporting other events and financial statements. The company was formerly known as Big Cypress Acquisiti
• SAB Biotherapeutics Files 8-K on Officer/Director Changes — May 8, 2024 Risk: medium
  SAB Biotherapeutics, Inc. filed an 8-K on May 8, 2024, reporting events as of May 3, 2024. The filing covers the departure of directors, election of directors,
• SAB Biotherapeutics Files 8-K on Stock and Warrants — Apr 15, 2024 Risk: low
  SAB Biotherapeutics, Inc. filed an 8-K on April 15, 2024, reporting an event on April 12, 2024. The filing pertains to their common stock and warrants, with spe
• SAB Biotherapeutics Announces Director Change and Filings — Mar 8, 2024 Risk: medium
  On March 5, 2024, SAB Biotherapeutics, Inc. announced the departure of Director Dr. Jonathan M. Rothberg and the appointment of Dr. Steven M. Deitcher as a new
• SAB Biotherapeutics Converts All Warrants to Common Stock — Feb 2, 2024
  SAB Biotherapeutics, Inc. filed an 8-K on February 2, 2024, reporting a significant change in its capital structure that occurred on January 30, 2024. The compa
• SABS Enters Material Agreement for Stock & Warrants at $11.50 Exercise Price — Jan 26, 2024
  SAB Biotherapeutics, Inc. (SABS) filed an 8-K on January 26, 2024, to report entering into a material definitive agreement. This agreement involves the issuance
• SAB Biotherapeutics Confirms Nasdaq Listing for Stock & Warrants — Jan 25, 2024
  SAB Biotherapeutics, Inc. (SABS) filed an 8-K on January 25, 2024, reporting an event that occurred on January 23, 2024. The filing primarily updates its regist
• SAB Biotherapeutics Confirms Nasdaq Listing, Warrant Details — Jan 19, 2024
  SAB Biotherapeutics, Inc. filed an 8-K on January 19, 2024, to disclose that its common stock, with a par value of $0.0001 per share, is registered on The Nasda
• SAB Biotherapeutics Amends Bylaws, Modifies Security Holder Rights — Jan 3, 2024
  SAB Biotherapeutics, Inc. filed an 8-K on January 3, 2024, reporting an event that occurred on January 2, 2024. The filing indicates material modifications to t

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX